{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:36:26Z","timestamp":1754163386477,"version":"3.41.2"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"None"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10637-025-01553-4","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T12:15:58Z","timestamp":1749471358000},"page":"742-749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characterizations, management, and prognosis in immune checkpoint inhibitor-induced myelitis"],"prefix":"10.1007","volume":"43","author":[{"given":"Yi-Xiao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Hang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Cong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Lei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"1553_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223\u2013249. https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741","journal-title":"Annu Rev Pathol"},{"issue":"7","key":"1553_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","volume":"9","author":"SJ Wang","year":"2023","unstructured":"Wang SJ, Dougan SK, Dougan M (2023) Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer 9(7):543\u2013553. https:\/\/doi.org\/10.1016\/j.trecan.2023.04.002","journal-title":"Trends Cancer"},{"key":"1553_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer (Oxford, England\u202f: 1990) 73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"issue":"1","key":"1553_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s1474-4422(23)00369-1","volume":"23","author":"A Farina","year":"2024","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Vogrig A, Zekeridou A, Mu\u00f1iz-Castrillo S, Velasco R et al (2024) Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol 23(1):81\u201394. https:\/\/doi.org\/10.1016\/s1474-4422(23)00369-1","journal-title":"Lancet Neurol"},{"key":"1553_CR5","doi-asserted-by":"publisher","unstructured":"Picca A, Berzero G, Bihan K, Jachiet V, Januel E, Coustans M et al (2021) Longitudinally extensive myelitis associated with immune checkpoint inhibitors. Neurol (R) Neuroimmunol Neuroinflammation 8(3). https:\/\/doi.org\/10.1212\/nxi.0000000000000967","DOI":"10.1212\/nxi.0000000000000967"},{"key":"1553_CR6","doi-asserted-by":"publisher","first-page":"1130313","DOI":"10.3389\/fneur.2023.1130313","volume":"14","author":"S Chatterton","year":"2023","unstructured":"Chatterton S, Xi S, Jia JX, Krause M, Long GV, Atkinson V et al (2023) Case series: immune checkpoint inhibitor-induced transverse myelitis. Front Neurol 14:1130313. https:\/\/doi.org\/10.3389\/fneur.2023.1130313","journal-title":"Front Neurol"},{"issue":"1","key":"1553_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12883-022-02987-6","volume":"22","author":"S Hirano","year":"2022","unstructured":"Hirano S, Kojima A, Nakayama Y, Takeda T, Kishimoto T, Takahashi T et al (2022) A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study. BMC Neurol 22(1):483. https:\/\/doi.org\/10.1186\/s12883-022-02987-6","journal-title":"BMC Neurol"},{"issue":"1","key":"1553_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12885-018-3997-2","volume":"18","author":"Y Narumi","year":"2018","unstructured":"Narumi Y, Yoshida R, Minami Y, Yamamoto Y, Takeguchi S, Kano K et al (2018) Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. BMC Cancer 18(1):95. https:\/\/doi.org\/10.1186\/s12885-018-3997-2","journal-title":"BMC Cancer"},{"key":"1553_CR9","doi-asserted-by":"publisher","first-page":"101447","DOI":"10.1016\/j.msard.2019.101447","volume":"37","author":"T Shimada","year":"2020","unstructured":"Shimada T, Hoshino Y, Tsunemi T, Hattori A, Nakagawa E, Yokoyama K et al (2020) Neuromyelitis optica spectrum disorder after treatment with pembrolizumab. Mult Scler Relat Disord 37:101447. https:\/\/doi.org\/10.1016\/j.msard.2019.101447","journal-title":"Mult Scler Relat Disord"},{"key":"1553_CR10","doi-asserted-by":"publisher","first-page":"102451","DOI":"10.1016\/j.msard.2020.102451","volume":"46","author":"S Nasralla","year":"2020","unstructured":"Nasralla S, Abboud H (2020) Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? Insights from checkpoint inhibitor immune-related adverse events. Mult Scler Relat Disord 46:102451. https:\/\/doi.org\/10.1016\/j.msard.2020.102451","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"1553_CR11","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1007\/s00415-021-10913-y","volume":"269","author":"D Weiss","year":"2022","unstructured":"Weiss D, Cantr\u00e9 D, Zettl UK, Storch A, Prudlo J (2022) Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab. J Neurol 269(5):2778\u20132780. https:\/\/doi.org\/10.1007\/s00415-021-10913-y","journal-title":"J Neurol"},{"issue":"2","key":"1553_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2019.4379","volume":"77","author":"A Kunchok","year":"2020","unstructured":"Kunchok A, Zekeridou A, Pittock S (2020) CRMP5-IgG-associated paraneoplastic myelopathy with PD-L1 inhibitor therapy. JAMA Neurol 77(2):255\u2013256. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4379","journal-title":"JAMA Neurol"},{"issue":"12","key":"1553_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1159\/000368316","volume":"37","author":"GM O'Kane","year":"2014","unstructured":"O\u2019Kane GM, Lyons TG, Colleran GC, Ahmad MW, Alken S, Kavanagh EC et al (2014) Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma. Oncol Res Treat 37(12):757\u2013760. https:\/\/doi.org\/10.1159\/000368316","journal-title":"Oncol Res Treat"},{"issue":"4","key":"1553_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16(4):589\u2013593. https:\/\/doi.org\/10.1093\/neuonc\/nou001","journal-title":"Neuro Oncol"},{"issue":"1","key":"1553_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40425-018-0393-z","volume":"6","author":"CA Garcia","year":"2018","unstructured":"Garcia CA, El-Ali A, Rath TJ, Contis LC, Gorantla V, Drappatz J et al (2018) Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer 6(1):83. https:\/\/doi.org\/10.1186\/s40425-018-0393-z","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1553_CR16","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acn3.547","volume":"5","author":"R Wilson","year":"2018","unstructured":"Wilson R, Menassa DA, Davies AJ, Michael S, Hester J, Kuker W et al (2018) Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Ann Clin Transl Neurol 5(5):640\u2013645. https:\/\/doi.org\/10.1002\/acn3.547","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"1553_CR17","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1007\/s00415-019-09562-z","volume":"266","author":"MAL Romeo","year":"2019","unstructured":"Romeo MAL, Garassino MC, Moiola L, Galli G, Comi G, Martinelli V et al (2019) Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. J Neurol 266(12):3163\u20133166. https:\/\/doi.org\/10.1007\/s00415-019-09562-z","journal-title":"J Neurol"},{"issue":"4","key":"1553_CR18","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.1212\/nxi.0000000000000773","volume":"7","author":"M Nowosielski","year":"2020","unstructured":"Nowosielski M, De Pauli F, Iglseder S, Wagner M, Hoellweger N, Nguyen VA et al (2020) Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors. Neurol (R) Neuroimmunol Neuroinflammation 7(4):e773. https:\/\/doi.org\/10.1212\/nxi.0000000000000773","journal-title":"Neurol (R) Neuroimmunol Neuroinflammation"},{"key":"1553_CR19","doi-asserted-by":"publisher","first-page":"8819296","DOI":"10.1155\/2020\/8819296","volume":"2020","author":"ML Vickers","year":"2020","unstructured":"Vickers ML, Seidl B, Bigby K, Chern B, Eriksson L, Hartnett G et al (2020) Inflammatory myeloradiculitis secondary to pembrolizumab: a case report and literature review. Case Rep Oncol Med 2020:8819296. https:\/\/doi.org\/10.1155\/2020\/8819296","journal-title":"Case Rep Oncol Med"},{"key":"1553_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ejca.2020.12.014","volume":"145","author":"S Basin","year":"2021","unstructured":"Basin S, Perrin J, Michot JM, Lambotte O, Cauquil C (2021) Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin\u00a0alpha4 therapy. Eur J Cancer (Oxford, England\u202f: 1990) 145:230\u2013233. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.014","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"1553_CR21","doi-asserted-by":"publisher","first-page":"655283","DOI":"10.3389\/fneur.2021.655283","volume":"12","author":"S Charabi","year":"2021","unstructured":"Charabi S, Engell-Noerregaard L, Nilsson AC, Sten\u00f6r C (2021) Case report: longitudinal extensive transverse myelitis with novel autoantibodies following two rounds of pembrolizumab. Front Neurol 12:655283. https:\/\/doi.org\/10.3389\/fneur.2021.655283","journal-title":"Front Neurol"},{"issue":"6","key":"1553_CR22","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s13760-020-01434-y","volume":"121","author":"E Januel","year":"2021","unstructured":"Januel E, Perol L, Arriv\u00e9 L, Alamowitch S, Fain O, Mekinian A (2021) Anti-PD1-R checkpoint inhibitor related severe relapsing myelitis. Acta Neurol Belg 121(6):1855\u20131857. https:\/\/doi.org\/10.1007\/s13760-020-01434-y","journal-title":"Acta Neurol Belg"},{"issue":"12","key":"1553_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1212\/wnl.0000000000200055","volume":"98","author":"Q Liu","year":"2022","unstructured":"Liu Q, Wang B, Zhao W (2022) MOG-IgG-associated demyelination induced by pembrolizumab treatment in a patient with malignant melanoma. Neurology 98(12):501\u2013502. https:\/\/doi.org\/10.1212\/wnl.0000000000200055","journal-title":"Neurology"},{"issue":"8","key":"1553_CR24","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1016\/j.cllc.2022.08.012","volume":"23","author":"T Owen","year":"2022","unstructured":"Owen T, Fung AS (2022) Combination intravenous immune globulin (IVIG) and high dose steroids for treatment of immune-related myelitis in a non-small cell lung cancer patient treated with pembrolizumab and palliative radiation treatment: a case report. Clin Lung Cancer 23(8):e563\u2013e567. https:\/\/doi.org\/10.1016\/j.cllc.2022.08.012","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"1553_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10637-021-01154-x","volume":"40","author":"L Wang","year":"2022","unstructured":"Wang L, Lou H, Li B, Li J, Yang YM (2022) Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer. Invest New Drugs 40(1):151\u2013156. https:\/\/doi.org\/10.1007\/s10637-021-01154-x","journal-title":"Invest New Drugs"},{"issue":"10","key":"1553_CR26","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1080\/00207454.2022.2050907","volume":"133","author":"A Esechie","year":"2023","unstructured":"Esechie A, Fang X, Banerjee P, Rai P, Thottempudi N (2023) A case report of longitudinal extensive transverse myelitis: immunotherapy related adverse effect vs. COVID-19 related immunization complications. Int J Neurosci 133(10):1120\u20131123. https:\/\/doi.org\/10.1080\/00207454.2022.2050907","journal-title":"Int J Neurosci"},{"issue":"1","key":"1553_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4166\/kjg.2023.054","volume":"82","author":"KH Kim","year":"2023","unstructured":"Kim KH, Baek YH, Kang YW, Yoon BA, Moon SY (2023) A case of transverse myelitis following treatment with atezolizumab for advanced hepatocellular carcinoma. Korean J Gastroenterol = Taehan Sohwagi Hakhoe chi 82(1):35\u201339. https:\/\/doi.org\/10.4166\/kjg.2023.054","journal-title":"Korean J Gastroenterol = Taehan Sohwagi Hakhoe chi"},{"issue":"4","key":"1553_CR28","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1097\/wno.0000000000001427","volume":"43","author":"NA Lambert-Cheatham","year":"2023","unstructured":"Lambert-Cheatham NA, Sakuru RC, Merati M, Tessema ST, Salbert LR, Ward JH et al (2023) A case of pembrolizumab-induced papillitis with transverse myelitis. J Neuro-ophthalmol Off J North Am Neuro-Ophthalmol Soc 43(4):e131\u2013e133. https:\/\/doi.org\/10.1097\/wno.0000000000001427","journal-title":"J Neuro-ophthalmol Off J North Am Neuro-Ophthalmol Soc"},{"issue":"4","key":"1553_CR29","doi-asserted-by":"publisher","first-page":"e200249","DOI":"10.1212\/nxi.0000000000200249","volume":"11","author":"SB Syc-Mazurek","year":"2024","unstructured":"Syc-Mazurek SB, Zhao-Fleming H, Guo Y, Tisavipat N, Chen JJ, Zekeridou A et al (2024) MOG antibody-associated disease in the setting of metastatic melanoma complicated by immune checkpoint inhibitor use. Neurol(R) Neuroimmunol Neuroinflammation 11(4):e200249. https:\/\/doi.org\/10.1212\/nxi.0000000000200249","journal-title":"Neurol(R) Neuroimmunol Neuroinflammation"},{"issue":"5","key":"1553_CR30","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1007\/s10072-023-07252-3","volume":"45","author":"M Pedrero Prieto","year":"2024","unstructured":"Pedrero Prieto M, Gorriz Romero D, G\u00f3mez Roch E, P\u00e9rez Miralles FC, Casanova Estruch B (2024) Neuromyelitis optica associated with the use of atezolizumab in a patient with advanced lung adenocarcinoma. Neurol Sci Off J Italian Neurol Soc Italian Soc Clin Neurophysiol 45(5):2199\u20132202. https:\/\/doi.org\/10.1007\/s10072-023-07252-3","journal-title":"Neurol Sci Off J Italian Neurol Soc Italian Soc Clin Neurophysiol"},{"issue":"2","key":"1553_CR31","doi-asserted-by":"publisher","first-page":"e200382","DOI":"10.1212\/nxi.0000000000200382","volume":"12","author":"KA DiMauro","year":"2025","unstructured":"DiMauro KA, Heber ME, Lee J, Cohen JA, Flanagan EP, Riley C et al (2025) Progressive myelitis in a 63-year-old woman: a case report from the national multiple sclerosis society case conference proceedings. Neurol(R) Neuroimmunol Neuroinflammation 12(2):e200382. https:\/\/doi.org\/10.1212\/nxi.0000000000200382","journal-title":"Neurol(R) Neuroimmunol Neuroinflammation"},{"issue":"4","key":"1553_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","volume":"19","author":"AM Haugh","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB (2020) Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf 19(4):479\u2013488. https:\/\/doi.org\/10.1080\/14740338.2020.1738382","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"1553_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","volume":"24","author":"KL Reynolds","year":"2019","unstructured":"Reynolds KL, Guidon AC (2019) Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist 24(4):435\u2013443. https:\/\/doi.org\/10.1634\/theoncologist.2018-0359","journal-title":"Oncologist"},{"issue":"16","key":"1553_CR34","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/wnl.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J et al (2021) Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96(16):754\u2013766. https:\/\/doi.org\/10.1212\/wnl.0000000000011795","journal-title":"Neurology"},{"issue":"2","key":"1553_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1055\/s-0032-1322586","volume":"32","author":"TW West","year":"2012","unstructured":"West TW, Hess C, Cree BA (2012) Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies. Semin Neurol 32(2):97\u2013113. https:\/\/doi.org\/10.1055\/s-0032-1322586","journal-title":"Semin Neurol"},{"issue":"4","key":"1553_CR36","doi-asserted-by":"publisher","first-page":"e1014","DOI":"10.1212\/nxi.0000000000001014","volume":"8","author":"F Graus","year":"2021","unstructured":"Graus F, Vogrig A, Mu\u00f1iz-Castrillo S, Antoine JG, Desestret V, Dubey D et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol(R) Neuroimmunol Neuroinflammation 8(4):e1014. https:\/\/doi.org\/10.1212\/nxi.0000000000001014","journal-title":"Neurol(R) Neuroimmunol Neuroinflammation"},{"issue":"36","key":"1553_CR37","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/jco.21.01440","journal-title":"J Clin Oncol"},{"issue":"7","key":"1553_CR38","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","volume":"78","author":"R Velasco","year":"2021","unstructured":"Velasco R, Villagr\u00e1n M, Jov\u00e9 M, Sim\u00f3 M, Vilari\u00f1o N, Alemany M et al (2021) Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol 78(7):864\u2013873. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0249","journal-title":"JAMA Neurol"},{"issue":"3","key":"1553_CR39","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/ene.15624","volume":"30","author":"A Dinoto","year":"2023","unstructured":"Dinoto A, Mantovani E, Ferrari S, Mariotto S, Tamburin S (2023) Cerebellar involvement associated with immune checkpoint inhibitors: a systematic review. Eur J Neurol 30(3):774\u2013781. https:\/\/doi.org\/10.1111\/ene.15624","journal-title":"Eur J Neurol"},{"issue":"7","key":"1553_CR40","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/cji.0000000000000364","volume":"44","author":"JBE Janssen","year":"2021","unstructured":"Janssen JBE, Leow TYS, Herbschleb KH, Gijtenbeek JMM, Boers-Sonderen MJ, Gerritsen WR et al (2021) Immune checkpoint inhibitor-related Guillain-Barr\u00e9 syndrome: a case series and review of the literature. J Immunother 44(7):276\u2013282. https:\/\/doi.org\/10.1097\/cji.0000000000000364","journal-title":"J Immunother"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01553-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01553-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01553-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:04:42Z","timestamp":1753934682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01553-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1553"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01553-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical review board approval was not required for this study as it was conducted retrospectively using anonymized data that did not contain sensitive personal information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}